Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 434

Results For "MIT"

5636 News Found

NITI Aayog releases a compendium of Ayush-based practices
News | July 02, 2022

NITI Aayog releases a compendium of Ayush-based practices

The compendium was released by Suman Bery, Vice-Chairman, NITI Aayog and Dr. Munjpara Mahendrabhai Kalubhai, Minister of State for Ayush and WCD.


Jubilant HollisterStier announces CAD 100 mn for Montreal facility
News | July 01, 2022

Jubilant HollisterStier announces CAD 100 mn for Montreal facility

The Government of Quebec, through its agent Investissement Quebec, is granting a loan of CAD 25 million


Lupin receives approval from USFDA for Paliperidone extended-release tablets
Drug Approval | July 01, 2022

Lupin receives approval from USFDA for Paliperidone extended-release tablets

Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of USD 152 million in the U.S


H Clinical adds commercial home health capabilities for pharma industry
News | July 01, 2022

H Clinical adds commercial home health capabilities for pharma industry

H Clinical is the leader in decentralized clinical trial support and home visits in Latin America


Akebia Therapeutics regaining rights to Vadadustat in the US, Europe and China
News | July 01, 2022

Akebia Therapeutics regaining rights to Vadadustat in the US, Europe and China

Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia


NADMED brings first CE-marked NAD+ analysis kit to the market
Medical Device | June 30, 2022

NADMED brings first CE-marked NAD+ analysis kit to the market

NADMED technology is based on proprietary extraction and the individual measurement of NAD metabolites


Weizmann’s study sheds new light on a promising antidepressant
Healthcare | June 30, 2022

Weizmann’s study sheds new light on a promising antidepressant

A newly revealed mechanism by Weizmann Institute of Science of ketamine’s action on potassium channels in neurons may lead to improved therapies for depression


MTPA announces long-term findings from post-marketing safety study of Radicava
News | June 30, 2022

MTPA announces long-term findings from post-marketing safety study of Radicava

Analysis of Post-Marketing Safety Data Shows Consistent Findings with Safety Profile Reported in Clinical Trials of Edaravone


Dr. Reddy's Laboratories announces conclusion of patent litigation with Indivior
News | June 30, 2022

Dr. Reddy's Laboratories announces conclusion of patent litigation with Indivior

The settlement and dismissal resolves all claims between the parties


Govt calls upon states to step up vigil against Covid
Policy | June 29, 2022

Govt calls upon states to step up vigil against Covid

States were also strongly advised to strictly monitor epidemiological profile of admitted COVID patients